SOLASTA® Bio, a pioneering agri-biotech firm specialising in advanced green insecticides, has announced a significant expansion of its intellectual property portfolio and a series of robust field trial results. These advancements underscore the broad potential of its peptide-based technology as a sustainable and effective crop protection solution amidst a growing global shift away from conventional chemical pesticides.
The company now possesses 14 granted patents for its proprietary peptides, including eight in the United States and six in Europe. This strengthened patent position is a critical component of SOLASTA® Bio’s global protection strategy, paving the way for the commercial deployment of its environmentally responsible crop protection products. The expanding portfolio also signals the company’s progress toward regulatory readiness and its commitment to delivering long-term value for agricultural partners and growers worldwide.
The global bioinsecticide market, valued at approximately $3.7 billion in 2023, is projected to reach $10.68 billion by 2032, expanding at a compound annual growth rate (CAGR) of 12.5%. This surge is largely driven by increasing consumer demand for organic food, rising awareness of the detrimental environmental and health impacts of synthetic pesticides, and supportive government regulations promoting sustainable agricultural practices like Integrated Pest Management (IPM).
Conventional chemical pesticides, while historically effective, increasingly face challenges such as pest resistance, harm to beneficial organisms like pollinators, and the accumulation of residues in soil, water, and food. The regulatory landscape, particularly in regions like the European Union, is also pushing for a significant reduction in the use of hazardous chemicals, with targets to cut chemical pesticide use by 50% by 2030.
Building on over 50 greenhouse and field trials, SOLASTA® Bio has broadened its testing program to include critical global staple crops such as rice, alongside ongoing evaluations on high-value leafy greens and soft fruit crops. This expanded trial footprint demonstrates the versatility and adaptability of its peptide-based platform across varied agricultural environments and geographies.
Recent trials conducted in Thailand have shown promising results against destructive plant hoppers in rice cultivation. These pests are notorious for causing “hopperburn,” a condition that can lead to 100% crop loss by sucking sap and transmitting viruses, often exacerbated by the overuse of traditional insecticides that eliminate natural predators. Simultaneously, trials in the U.S., UK, and Italy on berry crops, including strawberries, continue to exhibit strong efficacy against the invasive Spotted Wing Drosophila. This pest poses a significant threat to soft-skinned fruits, with females capable of laying eggs in healthy fruit, leading to substantial crop losses and increased reliance on frequent insecticide applications.
The company has also extended its trials to address Lepidoptera (moths and butterflies in their destructive caterpillar stage) and aphids on leafy vegetables across multiple territories. Lepidopteran larvae are major defoliators and can cause extensive damage to various crops, while aphids weaken plants, transmit viruses, and secrete sticky honeydew.
A key finding from almost all trials to date is the consistent high efficacy of SOLASTA® Bio’s peptide candidates, frequently matching or exceeding 85% control compared to existing commercial standards. Crucially, the trials have reported no observed phytotoxicity (harm to plants) and no negative impact on beneficial insects, including vital pollinators.
Shireen Davies, CEO and co-founder of SOLASTA® Bio, emphasised the significance of these milestones: “These patent grants represent a paradigm shift in crop protection, demonstrating that nature-inspired peptides can be effectively protected for commercial deployment. For potential partners and customers, this provides crucial confidence that our technology is not only highly effective but also commercially secure.”
Davies added, “Combined with our expanding field trials programme, these developments position SOLASTA Bio exceptionally well as we advance toward commercialisation. The breadth of our trials, from rice in Asia to soft fruit in Europe and the US, demonstrates the global applicability of our platform and our ability to address pest challenges across diverse crops and geographies.”
SOLASTA® Bio’s innovative technology harnesses insect ‘neuropeptides,’ small signaling molecules that regulate fundamental physiological processes in insects such as feeding, growth, and reproduction. By designing bioinsecticides that selectively disrupt these functions in target pests, the company aims to offer a precise and environmentally safe alternative to broad-spectrum chemical treatments, safeguarding non-target organisms like bees.
In Case You Missed It:
Further solidifying its operational capacity, SOLASTA® Bio recently bolstered its U.S. presence with the appointment of a new Field Trials Manager, aimed at supporting the acceleration of trial activities across North America. These achievements follow a highly successful, oversubscribed $14 million Series A funding round in September 2024. The round attracted prominent agricultural and life science investors, including Forbion BioEconomy Fund, FMC Ventures, and Corteva Catalyst, reflecting strong industry confidence in the company’s groundbreaking biological solutions.
